2024
Gardner, J., Hammond, S., Jensen, R., Gibson, A., Krantz, M. S., Ardern-Jones, M., . . . Naisbitt, D. J. (2024). Glycolysis: An early marker for vancomycin-specific T-cell activation.. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 54(1), 21-33. doi:10.1111/cea.14423DOI: 10.1111/cea.14423
2023
Ogese, M. O., Lister, A., Farrell, L., Gardner, J., Kafu, L., Ali, S. -E., . . . Naisbitt, D. J. (2023). A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment. TOXICOLOGICAL SCIENCES. doi:10.1093/toxsci/kfad101DOI: 10.1093/toxsci/kfad101
Almutairi, M., Lister, A., Zhao, Q., Line, J., Adair, K., Tailor, A., . . . Naisbitt, D. J. (2023). Activation of Human CD8+ T Cells with Nitroso Dapsone-Modified HLA-B*13:01-Binding Peptides.. Journal of immunology (Baltimore, Md. : 1950), 210(8), 1031-1042. doi:10.4049/jimmunol.2200531DOI: 10.4049/jimmunol.2200531
Glycolytic switching: An early indicator for drug-specific T-cell activation (Conference Paper)
Gardner, J., Hammond, S., Betts, C., Chadwick, A., & Naisbitt, D. (2023). Glycolytic switching: An early indicator for drug-specific T-cell activation. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 505). Retrieved from https://www.webofscience.com/
2022
Gardner, J. (2022, September 8). DETERMINING THE IMMUNOGENICITY OF GLYCOPEPTIDE ANTIBIOTICS IMPLICATED IN DRUG HYPERSENSITIVITY REACTIONS.
Hammond, S., Olsson-Brown, A., Grice, S., Gibson, A., Gardner, J., Castrejon-Flores, J. L., . . . Naisbitt, D. J. (2022). Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. TOXICOLOGICAL SCIENCES, 186(1), 58-69. doi:10.1093/toxsci/kfab144DOI: 10.1093/toxsci/kfab144
Gardner, J., Ogese, M., Betts, C. J., Pirmohamed, M., & Naisbitt, D. J. (2022). Characterization of Teicoplanin-Specific T-Cells from Drug Naïve Donors Expressing HLA-A*32:01.. Chemical research in toxicology, 35(2), 199-202. doi:10.1021/acs.chemrestox.1c00425DOI: 10.1021/acs.chemrestox.1c00425
2021
Ogese, M. O., Lister, A., Gardner, J., Meng, X., Alfirevic, A., Pirmohamed, M., . . . Naisbitt, D. J. (2021). Deciphering Adverse Drug Reactions: <i>In Vitro</i> Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. TOXICOLOGICAL SCIENCES, 183(1), 139-153. doi:10.1093/toxsci/kfab084DOI: 10.1093/toxsci/kfab084
Vaselli, N. M., Setiabudi, W., Subramaniam, K., Adams, E. R., Turtle, L., Iturriza-Gomara, M., . . . Hungerford, D. (2021). Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK. BMC INFECTIOUS DISEASES, 21(1). doi:10.1186/s12879-021-06443-7DOI: 10.1186/s12879-021-06443-7
Hammond, S., Olsson-Brown, A., Gardner, J., Thomson, P., Ali, S. -E., Jolly, C., . . . Naisbitt, D. (2021). T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(5). doi:10.1136/jitc-2021-002521DOI: 10.1136/jitc-2021-002521
Ogbe, A., Kronsteiner, B., Skelly, D. T., Pace, M., Brown, A., Adland, E., . . . Dunachie, S. (2021). T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-21856-3DOI: 10.1038/s41467-021-21856-3
Setiabudi, W., Hungerford, D., Subramaniam, K., Vaselli, N. M., Shaw, V. E., Wilton, M., . . . French, N. (2021). Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. BMJ Open, 11(3), e048317. doi:10.1136/bmjopen-2020-048317DOI: 10.1136/bmjopen-2020-048317
2020
